clinical trial · NCT05071612
Parallel Arm Trial of AD109 and AD504 In Patients With OSA
Apnimed·phase2·completed·n = 294
OSA - Obstructive Sleep ApneaAD109AD504Atomoxetine HydrochloridePlacebo
brief summary
This is a phase 2 randomized double-blind placebo-controlled parallel-arm dose finding study to compare fixed dose combinations of AD109 and AD504 to atomoxetine or placebo in Obstructive Sleep Apnea.
started
Nov 29, 2021
primary completion
Jul 20, 2022
completion
Aug 3, 2022
last updated
Aug 12, 2026
official title
Phase 2 Randomized Double-Blind Placebo-Controlled Parallel-Arm Dose Finding Study to Compare Fixed Dose Combinations of AD109 and AD504 to Atomoxetine or Placebo in Obstructive Sleep Apnea
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol